| Autor: |
Ibrahim El‐Battrawy, Katharina Koepsel, David Tenbrink, Boldizsar Kovacs, Tobias C. Dreher, Christian Blockhaus, Michael Gotzmann, Norbert Klein, Thomas Kuntz, Dong‐In Shin, Hendrik Lapp, Stephanie Rosenkaimer, Mohammad Abumayyaleh, Nazha Hamdani, Ardan Muammer Saguner, Jacqueline Kowitz, Julia W. Erath, Firat Duru, Andreas Mügge, Ibrahim Akin, Assem Aweimer, Thomas Beiert |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 18 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.123.030615 |
| Popis: |
Background Data on the use of the wearable cardioverter‐defibrillator (WCD) among patients with myocarditis remain sparse. Consequently, evidence for guideline recommendations in this patient population is lacking. Methods and Results In total, 1596 consecutive patients were included in a multicenter registry from 8 European centers, with 124 patients (8%) having received the WCD due to myocarditis and reduced left ventricular ejection fraction or prior ventricular tachyarrhythmia. The mean age was 51.6±16.3 years, with 74% being male. Patients were discharged after index hospitalization on heart failure medication: Angiotensin‐converting enzyme inhibitors (62.5%), angiotensin‐receptor‐neprilysin inhibitor (22.9%), aldosterone‐antagonists (51%), or beta blockers (91.4%). The initial median left ventricular ejection fraction was 30% (22%–45%) and increased to 48% (39%–55%) over long‐term follow‐up (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text